Cytochromes P450 and species differences in xenobiotic metabolism and activation of carcinogen

Environmental Health Perspectives

Volumn 106, Issue 10, 1998, Pages 633-641

  Lewis, David F V ^a   Ioannides, Costas ^a   Parke, Dennis V ^a  

^a UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

Carcinogenicity; Cytochromes P450; Metabolic activation; Species differences; Xenobiotic metabolism

Indexed keywords

CARCINOGEN; CHEMICAL AGENT; CYTOCHROME P450; XENOBIOTIC AGENT;

ARTICLE; CARCINOGENICITY; HUMAN; METABOLIC ACTIVATION; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; SAFETY; SPECIES DIFFERENCE; TOXICOLOGY; XENOBIOTIC METABOLISM;

ANIMALIA; RODENTIA;

EID: 0032427910     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.98106633     Document Type: Article

References (96)

1. Gori GB. Are animal tests relevant in cancer risk assessment? A persistent issue becomes uncomfortable. Regul Toxicol Pharmacol 13:225-227 (1991).
2. Gori GB. Adjudicating cancer causation: scientific political and legal conflicts. Regul Toxicol Pharmacol 13:309-325 (1991).
3. Gori GB. Cancer risk assessment the science that is not Regul Toxicol Pharmacol 16:10-20 (1992).
4. Lee M. Very alternative: non-animal safety tests. Chem Br 29:917-918 (1993).
5. Cohen SM. Human relevance of animal carcinogenicity studies. Regul Toxical Pharmacol 21:75-80 (1995).
6. Lawton G. The quest for valid alternatives. Chem Ind 10:375 (1997).
7. Ames BN, Gold LS. Too many rodent carcinogens: mitogenesis increases mutagenesis. Science 249:970-981 (1997).
8. Gold LS, Slone TH, Manley NB, Bernstein L. Target organs in chronic bioassays of 533 chemical carcinogens. Environ Health Perspect 93:233-246 (1991).
9. Ashby J, Paton D. The influence of chemical structure on the extent and sites of carcinogenesis for 522 rodent carcinogens and 55 different human carcinogen exposures. Mutat Res 286:3-74 (1993).
10. Fung VA, Huff J, Weisburger EK, Hoel DG. Predictive strategies for selecting 379 NCI/NTP chemicals evaluated for carcinogenic potential: scientific and public health impact. Fundam Appl Toxicol 20:413-436 (1993).
11. McGregor DB, Pangrekar J, Rosenkranz HS, Klopman G. A re-examination of the low prevalence of carcinogens in an early carcinogen screen. Regul Toxicol Pharmacol 19:97-105 (1994).
12. Stoloff L. An analysis of the 1987 list of IARC-identified human carcinogens and the correlated animal studies. Regul Toxicol Pharmacol 15:10-13 (1992).
13. Ennever FK, Noonan TJ, Rosenkranz HS. The predictivity of animal bioassays and short-term genotoxicity tests for carcinogenicity and non-carcinogenicity to humans. Mutagenesis 2:73-78 (1987).
14. Lijinsky W. Life-span and cancer the induction time of tumours in diverse animal species treated with nitrosodiethylamine. Carcinogenesis 14:2373-2375 (1993).
15. Tardiff RG, Lohman PHM, Wogan GN (eds). Methods to Assess DNA Damage and Repair: Interspecies Comparison. New York:Wiley, 1994.
16. Smith DA. Species differences in metabolism and pharmacokinetics: are we close to an understanding? Drug Metab Rev 23:355-373 (1991).
17. Nedelcheva V, Gut I. P450 in the rat and man: methods of investigation substrate specificities and relevance to cancer. Xenobiotica 24:1151-1175 (1994).
18. Boobis AR, Sesardic D, Murray BP, Edwards RJ, Singleton AM, Rich KJ, Murray S, de la Torre R, Segura J, Pelkonen O, et al. Species variation in the response of the cytochrome P-450 dependent monooxygenase system to inducers and inhibitors. Xenobiotica 20:1139-1161 (1990).
19. Guengerich FP. Comparisons of catalytic selectivity of cytochrome P450 subfamily enzymes from different species. Chem Biol Interact 106:161-182 (1997).
20. Omura T, Ishimura Y, Fujii-Kuriyama Y (eds). Cytochrome P-450. 2nd ed. Tokyo:Kodansha, 1993.
21. Ortiz de Montellano PR (ed). Cytochrome P450. 2nd ed. New York:Plenum, 1995.
22. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, et al. P450 superfamily: update on new sequences gene mapping accession numbers and nomenclature. Pharmacogenetics 6:1-42 (1996).
23. Lewis DFV. Cytochromes P450: Structure, Function and Mechanism. London:Taylor & Francis, 1996.
24. Ioannides C, Lewis DFV (eds). Drugs Diet and Disease. Volume 1: Mechanistic Approaches to Cancer. London:Ellis Horwood, 1995.
25. Ioannides C, Parke DV. The cytochrome P4501 gene family of microsomal hemoproteins and their role in the metabolic activation of chemicals. Drug Metab Rev 22:1-85 (1990).
26. Ioannides C, Parke DV. Induction of cytochrome P4501 as an indicator of potential chemical carcinogenesis. Drug Metab Rev 25:485-501 (1993).
27. Ioannides C, Lewis DFV, Parke DV. Mechanisms of chemical carcinogenesis and molecular parametric analysis in the safety evaluation of chemicals. In: Drugs, Diet and Disease. Volume 1: Mechanistic Approaches to Cancer (Ioannides C, Lewis DFV, eds). London:Ellis Horwood, 1995.
28. Gonzalez FJ, Gelboin HV. Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metab Rev 26:165-183 (1994).
29. Lewis DFV, Bird MG, Parke DV. Molecular modelling of CYP2E1 enzymes from rat, mouse and man: an explanation for species differences in butadiene metabolism and potential carcinogenicity and rationalization of CYP2E substrate specificity. Toxicology 118:93-113 (1997).
30. Ronis MJJ, Lindros KO, Ingelman-Sundberg M. The CYP2E subfamily. In: Cytochromes P450: Metabolic and Toxicological Aspects (Ioannides C, ed). Boca Raton, FL:CRC Press, 1996;211-239.
31. Parke DV, Ioannides C. In: Mouse Liver Carcinogenesis: Mechanisms and Species Comparisons (Stevenson DE, McClain RM, Popp JA, Slaga TG, Wood JM, Pitot HC, eds). New York:Alan Liss, 1990;215-230.
32. Parke DV. The cytochromes P450 and mechanisms of chemical carcinogenesis. Environ Health Perspect 102:852-853 (1994).
33. Martin AP, Palumbi SR. Body size, metabolic rate, generation time, and the molecular clock. Proc Natl Acad Sci USA 90:4087-4091 (1993).
34. Orr WC, Sohal RS. Extension of life-span by overexpression of superoxide dismutase and catalase in Drosophila melanogaster. Science 263:1128-1130 (1994).
35. Lorenz J, Glatt HR, Fleischmann R, Ferlinz R, Oesch F. Drug metabolism in man and its relationship to that in three rodent species: monooxygenase, epoxide hydrolase, and glutathione S-transferase activities in subcellular fractions of lung and liver. Biochem Med 32:43-56 (1984).
36. Guengerich FP (ed). Mammalian Cytochromes P-450. Boca Raton, FL:CRC Press, 1987.
37. Archakov AI, Bachmanova GI. Cytochrome P-450 and Active Oxygen. London:Taylor & Francis, 1990.
38. Gibson GG, Skett P. Introduction to Drug Metabolism. 2nd ed. London:Chapman and Hall London, 1994.
39. Ioannides C (ed). Cytochromes P450: Metabolic and Toxicological Aspects. Boca Raton, FL:CRC Press, 1996.
40. DiCarlo FJ. Carcinogenesis bioassay data: correlation by species and sex. Drug Metab Rev 15:409-413 (1984).
41. Schenkman JB, Griem H (eds). Cytochrome P450. Berlin:Springer-Verlag, 1993.
42. Wiseman H, Lewis DFV. The metabolism of tamoxifen by human cytochromes P450 is rationalized by molecular modelling of the enzyme-substrate interaction: potential importance to its proposed anticarcinogenic/carcinogenic actions. Carcinogenesis 17:1357-1360 (1996).
43. Parke DV, Ioannides C, Walker R (eds). Food, Nutrition and Chemical Toxicity. London:Smith-Gordon, 1993.
44. Seng JE, Gandy J, Tuturro A, Lipman R, Bronson RT, Parkinson A, Johnson W, Hart RW, Leakey JEA. Effects of caloric restriction on expression of testicular cytochrome P450 enzymes associated with the metabolic activation of carcinogens. Arch Biochem Biophys 335:42-52 (1996).
45. Manjgaladze M, Chen S, Frame LT, Seng JE, Duffy PH, Feuers RJ, Hart RW, Leakey JEA. Effects of caloric restriction on rodent drug and carcinogen metabolizing enzymes: implications for mutagenesis and cancer. Mutat Res 295:201-222 (1993).
46. Andersen ME, Krishnan K, Conolly RB, McClellan RO. Mechanistic toxicology research and biologically-based modeling: partners for improving quantitative risk assessments. CIIT Activities 12 (January):1-7 (1992).
47. Farmer P. Human exposure to carcinogens. MRC News (October):16-17 (1992).
48. Wiseman H, Kaur H, Halliwell B. DNA damage and cancer: measurement and mechanism. Cancer Lett 93:113-120 (1995).
49. Watson WP, Bleasdale C, Golding BT. Chemicals and cancer: estimating the risk. Chem Br 30:661-664 (1994).
50. Phillips JC, Anderson D. Predictive toxicology. Occup Health Rev (January/February): 27-30 (1993).
51. Lee Y, Buchanan BG, Klopman G, Dimayuga M, Rosenkranz HS. The potential of organ specific toxicity for predicting rodent carcinogenicity. Mutat Res 358:37-62 (1996).
52. Wilbourn J, Vainio H. Identification of carcinogenic risks - qualitative aspects. In: Chemical Safety (Richardson M, ed). New York:VCH Press, 1994;241-258.
53. McConnell EE. Historical review of the rodent bioassay and future directions. Regul Toxicol Pharmacol 21:38-43 (1995).
54. Sachse C, Brockmöller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60:284-295 (1997).
55. Lewis DFV, Lake BG. Molecular modelling of members of the P4502A subfamily: application to studies of enzyme specificity. Xenobiotica 25:585-598 (1995).
56. Negishi M, Iwasaki M, Juvonen RO, Sueyoshi T, Darden TA, Pedersen LG. Structural flexibility and functional versatility of cytochrome P450 and rapid evolution. Mutat Res 350:43-50 (1996).
57. Ashby J. Use of short-term tests in determining the genotoxicity or nongenotoxicity of chemicals. In: Mechanisms of Carcinogenesis in Risk Identification (Vainio H, Magee PN, McGregor DB, McMichael AJ, eds). Lyon:International Agency for Research on Cancer, 1992;135-164.
58. Ashby J, Tennant RW. Prediction of rodent carcinogenicity for 44 chemicals: results. Mutagenesis 9:7-15 (1994).
59. Tennant RW, Spalding J, Stasiewicz S, Ashby J. Prediction of the outcome of rodent carcinogenicity bioassays currently being conducted on 44 chemicals by the National Toxicology Program. Mutagenesis 5:3-14 (1990).
60. Rosenkranz HS, Pangrekar J, Klopman G. Similarities in the mechanisms of antibacterial activity (Microtox assay) and toxicity to vertebrates. Altern Lab Anim 21:489-500 (1993).
61. Bahler D, Bristol DW. The induction of rules for predicting chemical carcinogenesis in rodents in: Intelligent Systems for Molecular Biology (Hunter L, Sharlik J, Searls D, eds). Menlo Park, CA:MIT Press, 1993;29-37.
62. Maron D, Ames BN. Revised methods for the Salmonella mutagenicity test. Mutat Res 113:173-215 (1933).
63. Bogen KT. Improved prediction of carcinogenic potencies from mutagenic potencies for chemicals positive in rodents and the Ames test. Environ Mol Mutagen 25:37-49 (1995).
64. Ballantyne B, Marrs T, Turner P (eds). General and Applied Toxicology. London:Macmillan, 1995.
65. Lipnick RL. Outliers: their origin and use in the classification of molecular mechanisms of toxicity. Sci Total Environ 109/110:131-153 (1991).
66. Lewis DFV. Quantitative structure-activity relationships in substrates inducers and inhibitors of cytochrome P4501 (CYP1). Drug Metab Rev 19:1-62 (1997).
67. Goldberg L (ed). Structure-Activity Correlation as a Predictive Tool in Toxicology. Washington, DC:Hemisphere, 1983.
68. Lewis DFV. MO-QSARS: A review of molecular orbital-generated quantitative structure-activity relationships. Prog Drug Metab 12:205-255 (1990).
69. Lewis DFV. Computer-assisted methods in the evaluation of chemical toxicity. Rev Computational Chem 3:173-222 (1992).
70. Brinn MW, Payne MP, Walsh PT. Neural network prediction of mutagenicity using structure-property relationships. Trans Inst Chem Eng 71:337-339 (1993).
71. Richard AM. Application of SAR methods to non-congeneric data bases associated with carcinogenicity and mutagenicity: issues and approaches. Mutat Res 305:73-97 (1994).
72. Ashby J. Two million rodent carcinogens? The role of SAR and QSAR in their detection. Mutat Res 305:3-12 (1994).
73. Poso A, von Wright A, Gynther J. An empirical and theoretical study on mechanisms of mutagenic activity of hydrazine compounds. Mutat Res 332:63-71 (1995).
74. Magdo I, Ferenczy GG, Bencz Z. Prediction of carcinogenicity from molecular structure; modification and reinvestigation of the method. Cancer Lett 81:201-207 (1994).
75. Mersch-Sundermann V, Rosenkranz HS, Klopman G. Structural basis of the genotoxicity of polycyclic aromatic hydrocarbons. Mutagenesis 7:211-218 (1992).
76. Lewis DFV. COMPACT and the importance of frontier orbitals in toxicity mediated by the cytochrome P450 mono-exygenase system. Toxicol Mod 1:85-97 (1995).
77. Hansch C, Zhang L. Quantitative structure-activity relationships of cytochrome P-450. Drug Metab Rev 25:1-48 (1993).
78. Debnath AK, Shusterman AJ, Lopez de Compadre RL, Hansch C. The importance of the hydrophobic interaction in the mutagenicity of organic compounds. Mutat Res 305:63-72 (1994).
79. Balls M, Bridges J, Southee J (eds). Animals and Alternatives in Toxicology. London:Macmillan, 1991.
80. Wang S, Milne GWA. Applications of computers to toxicological research. Chem Res Toxicol 6:748-753 (1993).
81. Lewis DFV. Comparison between rodent carcinogenicity test results of 44 chemicals and a number of predictive systems. Regul Toxicol Pharmacol 20:215-222 (1994).
82. Benigni R, Giuliani A. Quantitative structure-activity relationship (QSAR) studies in genetic toxicology: mathematical models and the 'biological activity' term of the relationship. Mutat Res 306:181-186 (1994).
83. Benigni R, Richard AM. QSARs of mutagens and carcinogens: two case studies illustrating problems in the construction of models for noncongeneric chemicals. Mutat Res 371:29-49 (1996).
84. Nims RW, Lubet RA. The CYP2B subfamily. In: Cytochromes P450: Metabolic and Toxicological Aspects (Ioannides C, ed). Boca Raton, FL:CRC Press, 1996;135-160.
85. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drug carcinogens and toxic chemicals:studies with liver microsomes of 30 Japanese and 30 Caucasians. Pharmacol Exp Ther 270:414-423 (1994).
86. Goldstein JA, de Morais SMF. Biochemistry and molceular biology of the human CYP2C subfamily. Pharmacogenetics 4:285-299 (1994).
87. Andersson T, Miners JO, Veronese ME, Tassaneeyakul W, Tassaneeyakul W, Meyer UA, Birkett DJ. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 36:521-530 (1993).
88. Sarver JG, White D, Erhardt P, Bachmann K. Estimating xenobiotic half-lives in humans from rat data: influence of log P. Environ Health Perspect 105:1204-1209 (1997).
89. Lewis DFV, Langley GR. A validation study of the COMPACT and HazardExpert techniques with 40 chemicals. Mutat Res 369:157-174 (1996).
90. Lewis DFV, Ioannides C, Parke DV. An improved and updated version of the COMPACT procedure for the evaluation of P450-mediated chemical activation. Drug Metab Rev ( in press).
91. Sanderson DM, Earnshaw CG. Computer prediction of possible toxic action from chemical structure: the DEREK system. Hum Exp Toxicol 10:261-273 (1991).
92. Smithing MP, Darvas F. HazardExpert: an expert system for predicting chemical toxicity. In: Food Safety Assessment (Finley JW, Robinson SF, Armstrong DJ, eds). Washington, DC:American Chemical Society, 1992;191-200.
93. Enslein K, Borgstedt HH. A QSAR model for the estimation of carcinogenicity: example application to an azo-dye. Toxicol Lett 49:107-121 (1989).
94. Pratt WB, Taylor P. Principles of Drug Action. 3rd ed. New York:Churchill-Livingstone, 1990;365-422.
95. Okudaira K. Akiyama T, Iiyama Y, Nagasaka Y, Chiba K, Hayashi M. Prediction of intrinsic clearance of omeprazole in humans: in vivo-in vitro correlation and interspecies scaling [abstract]. In: Proceedings of the 4th International ISSX Meeting, 29-31 August 1995, Seattle, WA, 1995;63.
96. Guengerich FP. Human cytochrome P450 enzymes. In: Cytochrome P450 (Ortiz de Montellano PR, ed). 2nd ed. NewYork:Plenum, 1995;473-535.